Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Sanofi-Aventis S.A. (SNY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 112,459,344
  • Shares Outstanding, K 2,521,510
  • Annual Sales, $ 38,408 M
  • Annual Income, $ 4,864 M
  • 36-Month Beta 0.87
  • Price/Sales 2.79
  • Price/Cash Flow 9.64
  • Price/Book 1.77

Price Performance

See More
Period Period Low Period High Performance
1-Month
42.69 +1.25%
on 01/22/18
45.11 -4.18%
on 01/16/18
+0.27 (+0.64%)
since 12/22/17
3-Month
42.69 +1.25%
on 01/22/18
49.72 -13.05%
on 10/23/17
-6.28 (-12.69%)
since 10/20/17
52-Week
39.42 +9.65%
on 01/24/17
50.65 -14.66%
on 09/22/17
+2.88 (+7.13%)
since 01/20/17

Most Recent Stories

More News
Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Bioverativ Inc. (BIVV) on Behalf of Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. is investigating potential claims on behalf of Bioverativ Inc. (NASDAQ:BIVV) stockholders concerning the proposed acquisition of the company by Sanofi (NYSE:SNY)...

BIVV : 103.74 (+61.82%)
SNY : 43.22 (-3.09%)
Sanofi to Acquire Haemophilia Focused Bioverativ, Stock Dips

Sanofi (SNY) is set to acquire blood disorder focused biopharmaceutical company, Bioverativ, for $11.6 billion.

ALNY : 130.55 (+4.58%)
BIVV : 103.74 (+61.82%)
SNY : 43.22 (-3.09%)
BIIB : 344.20 (+0.52%)
Johnson Fistel, Announces Investigations of the Proposed Sales of Bioverativ Inc., and Juno Therapeutics, Inc.

Shareholder Rights Law Firm Johnson Fistel, LLP is investigating potential claims against Bioverativ Inc., and Juno Therapeutics, Inc., as detailed below:

BIVV : 103.74 (+61.82%)
JUNO : 85.80 (+26.53%)
SNY : 43.22 (-3.09%)
Will These 4 Large-Cap Drug Stocks Be Big Winners This Earnings Season?

Here is a look at four large-cap pharma and biotech stocks including Merck (MRK) that could surpass earnings expectations in the fourth quarter.

CELG : 102.71 (+0.06%)
MRK : 61.28 (-0.15%)
ABBV : 106.21 (+1.50%)
JUNO : 85.80 (+26.53%)
SNY : 43.22 (-3.09%)
ALXN : 123.24 (+1.81%)
BIIB : 344.20 (+0.52%)
Sanofi Appoints Dominique Carouge Executive Vice President Head of Business Transformation and Member of the Executive Committee

Press Release

SAN : 7.38 (+1.79%)
SNY : 43.22 (-3.09%)
CES 2018 Promises a Thrilling Year for Gaming Enthusiasts

During CES 2018, a number of companies displayed some extravagant products which are set to change the gaming experience entirely this year.

MSFT : 91.18 (+1.31%)
NVDA : 233.04 (+1.27%)
HPQ : 23.91 (+0.89%)
NTDOY : 54.8000 (+0.18%)
SNY : 43.22 (-3.09%)
Pharma Stock Roundup: Novo Nordisk Reveals Bid to Acquire Ablynx, Pfizer & Others at Healthcare Conference

Focus this week was on pipeline updates provided by several companies including Pfizer (PFE) at a healthcare conference while Novo Nordisk's bid to acquire Ablynx also made news.

NVO : 57.85 (+0.10%)
JNJ : 147.59 (+0.16%)
MRK : 61.28 (-0.15%)
PFE : 36.96 (+0.05%)
GSK : 38.38 (+0.47%)
SNY : 43.22 (-3.09%)
BMY : 63.18 (+1.45%)
Novo Nordisk's Ozempic Gets Canadian Approval for Diabetes

Novo Nordisk (NVO) announced that Health Canada has approved Ozempic to improve glycemic control in adults with type II diabetes mellitus.

AZN : 35.83 (+1.10%)
NVO : 57.85 (+0.10%)
MRK : 61.28 (-0.15%)
SNY : 43.22 (-3.09%)
Emergent Down on '18 View, Posts Preliminary '17 Results

Emergent (EBS) provides preliminary results for 2017 and its guidance for 2018. The results exceed management's outlook issued in November last year.

EBS : 50.23 (-1.88%)
EXEL : 28.99 (+3.54%)
GSK : 38.38 (+0.47%)
SNY : 43.22 (-3.09%)
AbbVie's Upadacitinib Gains Breakthrough Therapy Designation

AbbVie's (ABBV) atopic dermatitis (eczema) candidate, upadacitinib, gets breakthrough therapy status from the FDA.

CLDX : 2.79 (+1.09%)
ABBV : 106.21 (+1.50%)
REGN : 373.93 (+0.65%)
SNY : 43.22 (-3.09%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Sanofi-Aventis is a global pharmaceutical company that contributes to enhance life by providing medicines, vaccines, and integrated healthcare solutions adapted to local needs and means primarily in Europe and the United States. The company is engaged in the research, development, manufacture and marketing...

See More

Key Turning Points

2nd Resistance Point 44.92
1st Resistance Point 44.76
Last Price 43.21
1st Support Level 44.44
2nd Support Level 44.28

See More

52-Week High 50.65
Fibonacci 61.8% 46.36
Fibonacci 50% 45.03
Fibonacci 38.2% 43.71
Last Price 43.21
52-Week Low 39.42

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.